<DOC>
	<DOCNO>NCT00661440</DOCNO>
	<brief_summary>The purpose study investigate safety efficacy neramexane mesylate treatment congenital idiopathic nystagmus ( CIN ) comparison placebo . In addition , subgroup multiple sclerosis ( MS ) patient suffer acquire nystagmus include ; subgroup analyze exploratory manner .</brief_summary>
	<brief_title>Efficacy Safety Study Neramexane Treat Congenital Acquired Nystagmus</brief_title>
	<detailed_description />
	<mesh_term>Nystagmus , Pathologic</mesh_term>
	<mesh_term>Nystagmus , Congenital</mesh_term>
	<criteria>patient congenital idiopathic nystagmus acquire nystagmus subsequent multiple sclerosis male female outpatient age 18 80 year ( inclusive ) screen patient evidence neurologic disorder CIN congenital nystagmus due albinism retinal disease and/or acquire nystagmus ( exemption : secondary MS )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>